Discovered by KalVista, sebetralstat is an investigational novel, orally-administered therapy for the on-demand treatment of HAE. Sebetralstat works by targeting the kallikrein-kinin system …

Sebetralstat is an investigational new drug that is being evaluated for the treatment of hereditary angioedema. [1] It is a plasma kallikrein inhibitor. [2]

May 31, 2024 · Oral sebetralstat provided faster times to the beginning of symptom relief, reduction in attack severity, and complete attack resolution than placebo.

In KONFIDENT-S, sebetralstat has enabled patients to treat attacks early with a median time from attack onset to treatment of 9 minutes, demonstrated a consistent safety and efficacy profile …

Feb 11, 2023 · Sebetralstat (KalVista Pharmaceuticals) is a novel oral plasma kallikrein inhibitor that is in development for the on-demand treatment of hereditary angioedema attacks.

Dec 1, 2024 · Sebetralstat administered orally at doses of 300 mg or 600 mg for the on-demand treatment of HAE attacks is superior to placebo and resulted in a faster time to symptom relief, …

Sebetralstat, an oral plasma kallikrein (PKa) inhibitor, was evaluated in KONFIDENT,6 a randomized, double-blind, placebo-controlled, phase 3 crossover trial for on-demand treatment …

Abstract: Sebetralstat is a novel, potent, and selective oral plasma kallikrein inhibitor drug candidate in clinical development for the on-demand treatment of hereditary angioedema (HAE).

Jul 4, 2024 · Oral sebetralstat provided faster times to the beginning of symptom relief, reduction in attack severity, and complete attack resolution than placebo. (Funded by KalVista …

Aug 22, 2024 · What is sebetralstat for hereditary angioedema? Sebetralstat, formerly known as KVD900, is a small molecule being developed by Kalvista Pharmaceuticals for the on-demand …